SEC Filing Summary: Bausch Health Companies Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bausch Health Companies Inc. on December 26, 2025. The filing details the completion of a material definitive agreement involving an exchange offer for the Company's senior secured notes.
Key Financial Metrics and Transaction Details
- Transaction Type: Exchange of outstanding senior secured notes for new senior secured notes.
- New Debt Issued: $1.6 billion aggregate principal amount of 10.00% Senior Secured Notes due 2032.
- Debt Exchanged: Outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028.
- Interest Rate: New Notes bear an interest rate of 10.00%.
- Collateral: The notes are secured by a first priority lien on substantially all assets of the Issuer and guarantors, including a pledge of approximately 60% of the outstanding common shares of Bausch + Lomb Corporation.
- Cash Flow/Profit/Margins: The filing text does not provide specific values for revenue, profit, cash flow, or operating margins.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's debt profile. The Company replaced existing notes with varying maturities and interest rates (4.875% and 11.00%) with a unified series of 10.00% notes due 2032. Additionally, the collateral pledge for the debt was increased by the transfer of an additional 26,495,472 common shares of Bausch + Lomb, bringing the total pledged equity to approximately 60% of Bausch + Lomb's outstanding shares.
Guidance, Outlook, and Risks
- Management Commentary: The filing confirms the successful settlement of the exchange offer as previously announced.
- Regulatory Status: The New Notes were not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
- Risks/Contingencies: The New Notes are subject to a "Restricted Period" of at least 40 days post-settlement for notes sold under Regulation S, during which they carry a different CUSIP number and ISIN.
Key Facts for Investor Verification
- Verify the total principal amount of the 4.875% and 11.00% notes tendered in the exchange to confirm the full $1.6 billion was utilized.
- Confirm the exact interest payment schedule for the New Notes, noting they accrue interest from October 15, 2025.
- Review the Second Supplemental Indenture (Exhibit 4.2) for specific covenants and limitations on the first priority lien.
- Monitor the status of the pledged Bausch + Lomb shares to ensure the 60% ownership stake remains valid and unencumbered by other claims.